Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tabirafusp tedromer
- Development stage
- Phase 3
- Lead developer
- Kodiak Sciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Tabirafusp tedromer is an investigational recombinant fusion protein developed by Kodiak Sciences for the treatment of retinal diseases. It is a bispecific molecule that acts as a dual inhibitor of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF), designed to target both inflammatory and angiogenic pathways implicated in conditions such as neovascular (wet) age-related macular degeneration (AMD). The drug utilizes an antibody biopolymer conjugate (ABC) platform, aiming to provide durable efficacy with less frequent dosing compared to existing therapies. Tabirafusp tedromer is currently in phase 3 clinical trials for wet AMD, with additional development in earlier phases for diabetic macular oedema and preclinical studies for dry AMD[2][4][6][7].
- Other names
- tabirafusp alfa tedromer
02
Targets
IL-6 (Interleukin 6)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on tabirafusp tedromer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tabirafusp tedromer.